

# Key Figures (IFRS)\*

MORPHOSYS GROUP (in € million, if not stated otherwise)

	12/31/11	12/31/10	12/31/09	12/31/08	12/31/07	12/31/06	12/31/05	12/31/04	12/31/03
<b>RESULTS</b>									
Revenues	100.8	87.0	81.0	71.6	62.0	53.0	33.5	22.0	15.3
Cost of Goods Sold	7.0	7.3	6.7	7.1	7.9	8.0	2.5	0.9 <sup>1)</sup>	-
R&D Expenses	57.5	46.9	39.0	27.6	22.2	17.5	14.0	11.4 <sup>1)</sup>	9.0 <sup>1)</sup>
S, G&A Expenses	24.6	23.2	23.9	20.5	24.8	21.4	10.8	7.5 <sup>1)</sup>	7.2 <sup>1)</sup>
Personnel Expenses (Excluding Stock-based Compensation)	35.3	29.6	26.1	21.5	18.8	18.1	10.8	9.1	7.5
Capital Expenditure	3.6	13.8	3.8	3.8	12.0	4.0	0.7	1.7	0.7
Depreciation	2.4	2.1	1.6	1.5	1.5	1.5	0.9	0.7	0.5
Amortization of Intangible Assets	4.3	4.0	3.8	4.8	3.7	3.4	2.7	2.0	1.5
Profit/(Loss) from Operations	12.2	9.8	11.4	16.4	7.0	6.2	6.2	0.6	(3.1)
EBITDA	18.0	19.2	18.1	21.9	13.3	10.3	8.6	3.2	(0.4)
EBIT	11.1	13.1	12.8	16.5	8.3	5.4	5.3	0.5	(2.5)
Net Profit/(Loss)	8.2	9.2	9.0	13.2	11.5	6.0	4.7	0.3	(3.1)
<b>BALANCE SHEET</b>									
Total Assets	228.4 <sup>2)</sup>	209.8 <sup>2)</sup>	206.1	203.3	184.7	127.8	80.1	55.8	42.9
Cash, Cash Equivalents and Available-for-sale Financial Assets	134.4	108.4	135.1	137.9	106.9	66.0	53.6	37.2	23.2
Intangible Assets	66.0	69.2	17.4	19.7	22.3	14.8	12.4	12.8	14.5
Total Liabilities	31.3 <sup>2)</sup>	23.9 <sup>2)</sup>	32.2	41.3	39.2	27.8	16.1	16.4	15.6
Stockholders' Equity	197.1	185.9	173.9	162.0	145.5	100.1	64.0	39.4	27.3
Equity Ratio (in%)	86%	89%	84%	80%	79%	78%	80%	71%	64%
<b>MORPHOSYS SHARE</b>									
Number of Shares Issued	23,112,167	22,890,252	22,660,557	22,478,787	22,160,259	20,145,966	18,077,589	16,316,556	14,703,996
Earnings/(Loss) per Share, Diluted (in €)	0.36	0.40	0.40	0.59	0.53	0.31	0.28	0.02	(0.24)
Dividend (in €)	-	-	-	-	-	-	-	-	-
Share Price (in €)	17.53	18.53	17.04	18.75	16.10	18.12	13.77	12.70	3.71
<b>PERSONNEL DATA</b>									
Total Group Employees (Number)	446	464	404	334	295	279	172	132	95
Germany (Number)	352	370	301	236	192	183	145	132	95
Other Countries (Number)	94	94	103	98	103	96	27	-	-

\* MorphoSys is publishing its consolidated financial statements in accordance with IFRS since 2003. In earlier periods, the Company reported according to US GAAP.

<sup>1)</sup> Excluding stock-based compensation

<sup>2)</sup> In 2011, a deferred tax asset in the amount of € 2.3 million has been offset with a deferred tax liability for better transparency. Both deferred tax asset and deferred tax liability relate to income taxes levied by the same tax authority on the same taxable entity. To provide comparative information, prior year's deferred tax asset and deferred tax liability (€ 2.8 million) – and thus total assets as well as total liabilities and stockholders' equity – have been adjusted accordingly.